FDA — authorised 11 June 1963
- Marketing authorisation holder: ALLERGAN
- Status: approved
🇺🇸 Dendrid in United States
FDA authorised Dendrid on 11 June 1963
Marketing authorisations
FDA — authorised 11 June 1963
- Application: NDA013935
- Marketing authorisation holder: ALLERGAN
- Local brand name: HERPLEX
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 28 June 1963
- Application: NDA014169
- Marketing authorisation holder: ALCON
- Local brand name: DENDRID
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 6 April 1964
- Application: NDA013934
- Marketing authorisation holder: GLAXOSMITHKLINE
- Local brand name: STOXIL
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
FDA — authorised 2 September 1967
- Application: NDA015868
- Marketing authorisation holder: GLAXOSMITHKLINE
- Local brand name: STOXIL
- Indication: OINTMENT — OPHTHALMIC
- Status: approved
Dendrid in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Dendrid approved in United States?
Yes. FDA authorised it on 11 June 1963; FDA authorised it on 11 June 1963; FDA authorised it on 28 June 1963.
Who is the marketing authorisation holder for Dendrid in United States?
ALLERGAN holds the US marketing authorisation.